ZNF518B

Summary

ZNF518B (zinc finger protein 518B, HGNC:29365) is a protein-coding gene on chromosome 4p16.1, encoding Zinc finger protein 518B (Q9C0D4). Through its association with the EHMT1-EHMT2/G9A and PRC2/EED-EZH2 histone methyltransferase complexes may function in gene silencing, regulating repressive post-translational methylation of histone tails at promoters of target genes.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus.

Source: NCBI Gene 85460 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 195 total
• MANE Select transcript: NM_053042

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29365
Approved symbol	ZNF518B
Name	zinc finger protein 518B
Location	4p16.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1729
Ensembl gene	ENSG00000178163
Ensembl biotype	protein_coding
OMIM	617734
Entrez	85460

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000326756, ENST00000500268, ENST00000503068, ENST00000507515, ENST00000515072, ENST00000908724, ENST00000908725, ENST00000908726, ENST00000918783, ENST00000966268, ENST00000966269, ENST00000966270, ENST00000966271, ENST00000966272, ENST00000966273, ENST00000966274

RefSeq mRNA: 3 — MANE Select: NM_053042 NM_001375816, NM_001375817, NM_053042

CCDS: CCDS33960

Canonical transcript exons

ENST00000326756 — 3 exons

Exon	Start	End
ENSE00001289064	10439880	10446539
ENSE00001492103	10454805	10454988
ENSE00002084345	10457317	10457426

Expression profiles

Bgee: expression breadth ubiquitous, 240 present calls, max score 90.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.6483 / max 91.0908, expressed in 1599 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
51373	7.0503	1576
51372	2.5980	1235

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.96	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.84	silver quality
left ventricle myocardium	UBERON:0006566	90.22	silver quality
cortical plate	UBERON:0005343	88.99	gold quality
adrenal tissue	UBERON:0018303	88.91	gold quality
myocardium	UBERON:0002349	88.09	silver quality
ganglionic eminence	UBERON:0004023	87.92	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.65	gold quality
endothelial cell	CL:0000115	86.60	gold quality
ventricular zone	UBERON:0003053	86.17	gold quality
heart right ventricle	UBERON:0002080	85.63	gold quality
ileal mucosa	UBERON:0000331	85.51	gold quality
Brodmann (1909) area 23	UBERON:0013554	85.45	gold quality
middle temporal gyrus	UBERON:0002771	85.20	gold quality
epithelium of nasopharynx	UBERON:0001951	84.72	gold quality
pigmented layer of retina	UBERON:0001782	84.62	gold quality
tibialis anterior	UBERON:0001385	84.22	gold quality
parotid gland	UBERON:0001831	84.14	gold quality
placenta	UBERON:0001987	83.59	gold quality
cauda epididymis	UBERON:0004360	83.53	gold quality
deltoid	UBERON:0001476	83.37	silver quality
parietal pleura	UBERON:0002400	83.04	gold quality
biceps brachii	UBERON:0001507	82.19	gold quality
seminal vesicle	UBERON:0000998	82.12	gold quality
islet of Langerhans	UBERON:0000006	81.99	gold quality
bone marrow cell	CL:0002092	81.92	gold quality
quadriceps femoris	UBERON:0001377	81.39	silver quality
calcaneal tendon	UBERON:0003701	81.18	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	81.14	gold quality
muscle tissue	UBERON:0002385	80.88	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	4.81

Regulation

Is transcription factor: yes

JASPAR motifs

Motif	Name	Family
MA2586.1	ZNF518B	Factors with multiple dispersed zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605530

miRNA regulators (miRDB)

160 targeting ZNF518B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 3)

• CLNK and ZNF518B SNPs may have potential as diagnostic and prognostic marker for Chinese gout patients. (PMID:25591661)
• SLC2A9 and ZNF518B polymorphisms correlate with gout-related metabolic indices in Chinese Tibetan populations (PMID:26345926)
• ZNF518B exhibits a pattern of isoform abundance dependent on KRAS G13D and G12D mutations. (PMID:27805251)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp518b	ENSMUSG00000046572
rattus_norvegicus	Zfp518b	ENSRNOG00000028534
drosophila_melanogaster	hb	FBGN0001180
drosophila_melanogaster	CG12391	FBGN0033581
caenorhabditis_elegans		WBGENE00001824
caenorhabditis_elegans		WBGENE00012385

Paralogs (29): ZNF446 (ENSG00000083838), REST (ENSG00000084093), ZNF174 (ENSG00000103343), OVOL3 (ENSG00000105261), PLAGL1 (ENSG00000118495), ZSCAN18 (ENSG00000121413), ZNF576 (ENSG00000124444), OVOL2 (ENSG00000125850), PLAGL2 (ENSG00000126003), ZSCAN5A (ENSG00000131848), ZSCAN29 (ENSG00000140265), ZSCAN32 (ENSG00000140987), ZSCAN1 (ENSG00000152467), ZNF18 (ENSG00000154957), ZKSCAN2 (ENSG00000155592), ZNF496 (ENSG00000162714), ZNF202 (ENSG00000166261), ZNF641 (ENSG00000167528), ZNF444 (ENSG00000167685), SCAND1 (ENSG00000171222), ZNF274 (ENSG00000171606), ZNF131 (ENSG00000172262), OVOL1 (ENSG00000172818), ZNF518A (ENSG00000177853), PLAG1 (ENSG00000181690), ZSCAN5B (ENSG00000197213), ZNF770 (ENSG00000198146), PEG3 (ENSG00000198300), ZSCAN5C (ENSG00000204532)

Protein

Protein identifiers

Zinc finger protein 518B — Q9C0D4 (reviewed: Q9C0D4)

All UniProt accessions (2): Q9C0D4, D6RDM9

UniProt curated annotations — full annotation on UniProt →

Function. Through its association with the EHMT1-EHMT2/G9A and PRC2/EED-EZH2 histone methyltransferase complexes may function in gene silencing, regulating repressive post-translational methylation of histone tails at promoters of target genes.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (3): NP_001362745, NP_001362746, NP_444270* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

UniProt features (23 total): cross-link 7, compositionally biased region 4, region of interest 4, zinc finger region 3, sequence variant 3, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C0D4-F1	43.49	0.02

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 482, 491, 558, 594, 809, 846, 860

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 107 (showing top): AGTCTTA_MIR499, chr4p16, AGCATTA_MIR155, AAGCACA_MIR218, NUYTTEN_NIPP1_TARGETS_DN, TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN, BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_TRANS, DURAND_STROMA_NS_UP, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GCNP_SHH_UP_EARLY.V1_DN, MTOR_UP.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, ZNF213_TARGET_GENES, ZNF618_TARGET_GENES, GSE10240_CTRL_VS_IL17_AND_IL22_STIM_PRIMARY_BRONCHIAL_EPITHELIAL_CELLS_DN

GO Biological Process (2): chromatin organization (GO:0006325), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (4): DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA binding (GO:0003677), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular component organization	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
transition metal ion binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF518B	WDR1	O75083	623
ZNF518B	AMER3	Q8N944	585
ZNF518B	SLC2A9	Q9NRM0	520
ZNF518B	GNPNAT1	Q96EK6	495
ZNF518B	EPDR1	Q9UM22	464
ZNF518B	EZH2	Q15910	422
ZNF518B	CLNK	Q7Z7G1	419
ZNF518B	KLF14	Q8TD94	405
ZNF518B	FHL2	Q14192	385
ZNF518B	SP6	Q3SY56	381
ZNF518B	TMEM54	Q969K7	381
ZNF518B	DEFB131A	P59861	368
ZNF518B	WIZ	O95785	357
ZNF518B	ZNF730	Q6ZMV8	349
ZNF518B	PHTF2	Q8N3S3	346

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CHCHD4	ENSA	psi-mi:“MI:0914”(association)	0.530
CBX1	ZNF292	psi-mi:“MI:0914”(association)	0.530
IKZF5	PEX14	psi-mi:“MI:0914”(association)	0.350
VPS35	ILVBL	psi-mi:“MI:0914”(association)	0.350
H2BC21	SMCHD1	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
CBX3	ZNF324	psi-mi:“MI:0914”(association)	0.350
CBX3	MYL12B	psi-mi:“MI:0914”(association)	0.350
CBX5	ZNF292	psi-mi:“MI:0914”(association)	0.350
CTBP1	SEC16A	psi-mi:“MI:2364”(proximity)	0.270
HOXA2	GPX1	psi-mi:“MI:2364”(proximity)	0.270
KLF15	ZNF292	psi-mi:“MI:2364”(proximity)	0.270
SOX7	NFIB	psi-mi:“MI:2364”(proximity)	0.270
HOXB2	KMT2D	psi-mi:“MI:2364”(proximity)	0.270
HNRNPC	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
QKI	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
ZRANB2	SBNO1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (23): ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Proximity Label-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Affinity Capture-MS), ZNF518B (Proximity Label-MS), ZNF518B (Proximity Label-MS), ZNF518B (Proximity Label-MS), ZNF518B (Proximity Label-MS), ZNF518B (Proximity Label-MS)

ESM2 similar proteins: A0A087WXM9, A1L2H3, A4D1E1, A6QNQ6, A8MVM7, D3Z987, E1BC15, E5FYH0, E5FYH1, F6ULY3, F7DF15, G3S077, G7H7V7, G7NY55, O13859, O60673, P38398, P51587, P97929, Q0VBV7, Q3TNU4, Q3V089, Q4QY64, Q56UN5, Q5DTT3, Q5VWN6, Q61493, Q6J6I8, Q6J6I9, Q6J6J0, Q6P0N0, Q6ZP01, Q7Z333, Q7Z570, Q80WQ8, Q864S8, Q864U1, Q86WS4, Q86XD8, Q8IXS0

Diamond homologs: B2RRE4, B2RRF6, Q2I689, Q499R0, Q6AHZ1, Q9C0D4, Q9UM63, B0XS89, B1WBU4, J9VE33, P54785, P80944, Q0VCJ6, Q29419, Q58NQ5, Q5SVQ8, Q5U2T6, Q65XX7, Q6DJT9, Q6P882, Q811F1, Q96BR9, Q9CWH1, Q9QYE0, Q9UPG8, A1L2U9, B1WAZ8, Q0IH98, Q01611, Q95LI3, A0A1V6NWD3, O77459, P28166, P39956, P60319, Q02027, Q03833, Q10938, Q14119, Q292R5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

195 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	170
Likely benign	14
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

709 predictions. Top by Δscore:

Variant	Effect	Δscore
4:10454803:A:AC	donor_gain	1.0000
4:10454804:C:CC	donor_gain	1.0000
4:10454806:T:TA	donor_gain	1.0000
4:10457312:CTTA:C	donor_loss	1.0000
4:10457313:TTA:T	donor_loss	1.0000
4:10457315:A:AC	donor_gain	1.0000
4:10457315:AC:A	donor_gain	1.0000
4:10457316:C:CC	donor_gain	1.0000
4:10457316:CC:C	donor_gain	1.0000
4:10457316:CCCGG:C	donor_gain	1.0000
4:10446540:C:CC	acceptor_gain	0.9900
4:10454803:ACTT:A	donor_gain	0.9900
4:10454804:CTTC:C	donor_gain	0.9900
4:10457315:ACC:A	donor_gain	0.9900
4:10457316:CCC:C	donor_gain	0.9900
4:10457316:CCCG:C	donor_gain	0.9900
4:10446456:A:AC	donor_gain	0.9800
4:10454807:C:A	donor_gain	0.9800
4:10454810:G:A	donor_gain	0.9800
4:10446457:A:C	donor_gain	0.9700
4:10446538:CA:C	acceptor_gain	0.9700
4:10450860:C:CT	acceptor_gain	0.9700
4:10456823:T:TA	donor_gain	0.9600
4:10454804:CTT:C	donor_gain	0.9500
4:10446440:T:TA	donor_gain	0.9400
4:10454868:T:TA	donor_gain	0.9400
4:10454635:C:A	donor_gain	0.9300
4:10456612:C:A	donor_gain	0.9300
4:10452854:T:TA	donor_gain	0.9200
4:10454816:AG:A	donor_gain	0.9100

AlphaMissense

7092 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:10443165:C:T	G1055D	1.000
4:10443176:C:A	W1051C	1.000
4:10443176:C:G	W1051C	1.000
4:10443178:A:G	W1051R	1.000
4:10443178:A:T	W1051R	1.000
4:10443217:A:G	C1038R	1.000
4:10443492:A:G	L946S	1.000
4:10443501:A:T	V943D	1.000
4:10445837:A:C	C164W	1.000
4:10445839:A:G	C164R	1.000
4:10445903:G:C	F142L	1.000
4:10445903:G:T	F142L	1.000
4:10445905:A:G	F142L	1.000
4:10445911:A:G	C140R	1.000
4:10445918:A:C	C137W	1.000
4:10445920:A:G	C137R	1.000
4:10443153:A:G	L1059S	0.999
4:10443155:A:C	H1058Q	0.999
4:10443155:A:T	H1058Q	0.999
4:10443157:G:C	H1058D	0.999
4:10443159:C:G	R1057P	0.999
4:10443177:C:G	W1051S	0.999
4:10443206:A:C	C1041W	0.999
4:10443207:C:T	C1041Y	0.999
4:10443208:A:G	C1041R	0.999
4:10443209:A:C	F1040L	0.999
4:10443209:A:T	F1040L	0.999
4:10443210:A:G	F1040S	0.999
4:10443211:A:G	F1040L	0.999
4:10443214:A:G	W1039R	0.999

dbSNP variants (sampled 300 via entrez): RS1000056824 (4:10442822 A>C,G), RS1000076579 (4:10452221 C>G,T), RS1000151484 (4:10443468 G>A), RS1000176881 (4:10460139 T>A,C,G), RS1000182371 (4:10446201 A>T), RS1000229108 (4:10460275 A>G), RS1000286419 (4:10440645 T>C), RS1000332213 (4:10451337 G>A), RS1000503843 (4:10443114 T>C,G), RS1000515413 (4:10456292 C>A), RS1000520786 (4:10458982 G>T), RS1000574592 (4:10459257 T>C), RS1000680758 (4:10453365 G>C), RS10007352 (4:10446055 C>T), RS1000739733 (4:10461366 G>C)

Disease associations

OMIM: gene MIM:617734 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004574_6	Skin aging (microtopography measurement)	7.000000e-06
GCST008971_36	Urate levels	0.000000e+00
GCST008971_37	Urate levels	9.000000e-59
GCST010512_3	Serum uric acid levels	3.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0004761	uric acid measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, decreases methylation, increases expression, affects cotreatment	7
trichostatin A	affects cotreatment, decreases expression, increases expression	3
sodium arsenite	affects methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
TAK-243	increases sumoylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
potassium chromate(VI)	increases expression	1
nickel sulfate	decreases expression	1
avobenzone	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Temozolomide	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Doxorubicin	decreases expression	1
Folic Acid	decreases expression	1
Formaldehyde	decreases expression	1
Ketoconazole	increases expression	1
Dihydrotestosterone	increases expression	1
Vanadates	decreases expression	1
Antirheumatic Agents	increases expression	1
Lactic Acid	decreases expression	1
Magnetite Nanoparticles	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety